QQQ   431.09 (+0.01%)
AAPL   169.13 (-2.06%)
MSFT   415.99 (+0.57%)
META   501.55 (+0.26%)
GOOGL   154.37 (-0.32%)
AMZN   184.26 (+0.35%)
TSLA   156.78 (-2.91%)
NVDA   871.04 (+1.28%)
AMD   163.71 (+2.11%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   15.96 (-1.72%)
F   12.04 (-1.55%)
MU   120.25 (-0.92%)
GE   154.25 (+0.36%)
CGC   6.74 (-3.44%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.81 (-0.39%)
PYPL   63.79 (+0.44%)
XOM   118.94 (-0.62%)
QQQ   431.09 (+0.01%)
AAPL   169.13 (-2.06%)
MSFT   415.99 (+0.57%)
META   501.55 (+0.26%)
GOOGL   154.37 (-0.32%)
AMZN   184.26 (+0.35%)
TSLA   156.78 (-2.91%)
NVDA   871.04 (+1.28%)
AMD   163.71 (+2.11%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   15.96 (-1.72%)
F   12.04 (-1.55%)
MU   120.25 (-0.92%)
GE   154.25 (+0.36%)
CGC   6.74 (-3.44%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.81 (-0.39%)
PYPL   63.79 (+0.44%)
XOM   118.94 (-0.62%)
QQQ   431.09 (+0.01%)
AAPL   169.13 (-2.06%)
MSFT   415.99 (+0.57%)
META   501.55 (+0.26%)
GOOGL   154.37 (-0.32%)
AMZN   184.26 (+0.35%)
TSLA   156.78 (-2.91%)
NVDA   871.04 (+1.28%)
AMD   163.71 (+2.11%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   15.96 (-1.72%)
F   12.04 (-1.55%)
MU   120.25 (-0.92%)
GE   154.25 (+0.36%)
CGC   6.74 (-3.44%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.81 (-0.39%)
PYPL   63.79 (+0.44%)
XOM   118.94 (-0.62%)
QQQ   431.09 (+0.01%)
AAPL   169.13 (-2.06%)
MSFT   415.99 (+0.57%)
META   501.55 (+0.26%)
GOOGL   154.37 (-0.32%)
AMZN   184.26 (+0.35%)
TSLA   156.78 (-2.91%)
NVDA   871.04 (+1.28%)
AMD   163.71 (+2.11%)
NIO   3.81 (-2.06%)
BABA   69.39 (-1.74%)
T   15.96 (-1.72%)
F   12.04 (-1.55%)
MU   120.25 (-0.92%)
GE   154.25 (+0.36%)
CGC   6.74 (-3.44%)
DIS   114.14 (+1.05%)
AMC   2.66 (+7.69%)
PFE   25.81 (-0.39%)
PYPL   63.79 (+0.44%)
XOM   118.94 (-0.62%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$163.35
+1.0%
$176.23
$130.96
$182.89
$289.24B0.585.62 million shs1.46 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$109.22
+0.3%
$114.67
$89.67
$121.64
$189.52B0.745.52 million shs1.93 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$125.71
-0.4%
$126.28
$99.14
$133.10
$318.43B0.388.32 million shs1.33 million shs
Novartis AG stock logo
NVS
Novartis
$93.33
-1.1%
$98.82
$92.19
$108.78
$197.82B0.541.48 million shs459,047 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.81
-0.4%
$27.27
$25.61
$41.33
$146.15B0.6142.25 million shs7.68 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.38%-4.82%-9.11%+0.12%+0.05%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.20%-1.46%-5.71%-4.28%+4.74%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.36%-0.32%+3.84%+6.50%+9.44%
Novartis AG stock logo
NVS
Novartis
+0.94%-1.14%-2.95%-12.36%-3.56%
Pfizer Inc. stock logo
PFE
Pfizer
+0.15%-2.56%-7.30%-8.51%-37.12%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9022 of 5 stars
2.45.04.23.92.52.52.5
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9921 of 5 stars
3.45.04.24.52.62.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.872 of 5 stars
2.35.03.34.12.82.52.5
Novartis AG stock logo
NVS
Novartis
2.1704 of 5 stars
2.13.02.50.01.70.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9913 of 5 stars
3.25.04.24.82.61.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.438.62% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.77
Moderate Buy$122.1411.83% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.254.41% Upside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$104.3311.79% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8842.87% Upside

Current Analyst Ratings

Latest NVS, MRK, PFE, ABBV, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $128.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$139.00 ➝ $142.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $135.00
3/22/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$188.00 ➝ $190.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.32$15.92 per share10.26$5.78 per share28.26
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.73$6.37 per share17.15$22.36 per share4.88
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.30$3.04 per share41.33$14.85 per share8.47
Novartis AG stock logo
NVS
Novartis
$45.44B4.35$10.69 per share8.73$22.06 per share4.23
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.50$2.97 per share8.69$15.81 per share1.63

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7359.8413.412.078.95%162.28%14.62%4/26/2024 (Confirmed)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2633.5021.292.6314.27%20.65%10.67%4/17/2024 (Confirmed)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14897.9312.790.500.61%9.33%3.61%4/25/2024 (Confirmed)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.1813.0011.721.4529.83%29.90%12.97%4/23/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3671.699.351.163.62%10.88%4.91%5/1/2024 (Confirmed)

Latest NVS, MRK, PFE, ABBV, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
4/25/2024N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.12N/A-$2.12N/AN/AN/A  
4/17/2024N/A
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.95$0.95N/AN/AN/AN/A  
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Novartis AG stock logo
NVS
Novartis
$1.64$1.53-$0.11-$1.08$11.69 billion$11.42 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/24/202412/31/2023
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.19$1.19N/A$1.47$10.19 billion$10.24 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.80%+7.84%227.11%52 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.01%+12.31%67.48%53 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.45%+6.08%2,200.00%13 Years
Novartis AG stock logo
NVS
Novartis
$2.462.64%+4.26%34.26%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.51%+2.57%466.67%15 Years

Latest NVS, MRK, PFE, ABBV, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
1/23/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.6%3/14/20243/15/20244/5/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Novartis AG stock logo
NVS
Novartis
0.39
1.15
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.47%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.20%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.12 billion2.12 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

NVS, MRK, PFE, ABBV, and ABT Headlines

SourceHeadline
SVB Wealth LLC Sells 35,727 Shares of Pfizer Inc. (NYSE:PFE)SVB Wealth LLC Sells 35,727 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 16 at 11:27 AM
Pfizers (PFE) Overweight Rating Reaffirmed at Cantor FitzgeraldPfizer's (PFE) Overweight Rating Reaffirmed at Cantor Fitzgerald
americanbankingnews.com - April 16 at 4:26 AM
Why the Market Dipped But Pfizer (PFE) Gained TodayWhy the Market Dipped But Pfizer (PFE) Gained Today
zacks.com - April 15 at 6:51 PM
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A TalkPfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
seekingalpha.com - April 15 at 5:39 PM
Pfizer (NYSE:PFE) Trading Up 0.7%Pfizer (NYSE:PFE) Trading Up 0.7%
marketbeat.com - April 15 at 3:37 PM
A Closer Look at Pfizers Options Market DynamicsA Closer Look at Pfizer's Options Market Dynamics
benzinga.com - April 15 at 12:38 PM
Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)Cullen Investment Group LTD. Takes Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 15 at 11:27 AM
Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)Cantor Fitzgerald Reaffirms "Overweight" Rating for Pfizer (NYSE:PFE)
marketbeat.com - April 15 at 11:21 AM
Is Pfizer Stock a Buy?Is Pfizer Stock a Buy?
fool.com - April 15 at 8:45 AM
Pfizer’s Velsipity UK approval to raise competition in ulcerative colitis marketPfizer’s Velsipity UK approval to raise competition in ulcerative colitis market
biopharma-reporter.com - April 15 at 7:37 AM
Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.Want $1,000 in Annual Dividend Income? Invest $13,200 in These Ultra-High-Yield Dividend Stocks.
fool.com - April 15 at 4:53 AM
Conning Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)Conning Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 14 at 3:45 PM
Pfizer (NYSE:PFE) Trading Down 0.8%Pfizer (NYSE:PFE) Trading Down 0.8%
americanbankingnews.com - April 14 at 3:12 AM
Lecap Asset Management Ltd. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE)Lecap Asset Management Ltd. Invests $1.32 Million in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 13 at 8:17 PM
Pfizer wins pause on Modernas COVID-19 patent lawsuitPfizer wins pause on Moderna's COVID-19 patent lawsuit
reuters.com - April 13 at 7:22 PM
The Smartest Dividend Stocks to Buy With $400 Right NowThe Smartest Dividend Stocks to Buy With $400 Right Now
fool.com - April 13 at 5:47 AM
Pfizer Inc. (NYSE:PFE) to Post Q1 2025 Earnings of $0.59 Per Share, Zacks Research ForecastsPfizer Inc. (NYSE:PFE) to Post Q1 2025 Earnings of $0.59 Per Share, Zacks Research Forecasts
americanbankingnews.com - April 13 at 3:08 AM
Pfizer Inc. (NYSE:PFE) Stock Position Lessened by Xcel Wealth Management LLCPfizer Inc. (NYSE:PFE) Stock Position Lessened by Xcel Wealth Management LLC
marketbeat.com - April 12 at 7:27 PM
Pfizers Innovative Drug Pipeline Provides Ample Reason To Buy It HerePfizer's Innovative Drug Pipeline Provides Ample Reason To Buy It Here
seekingalpha.com - April 12 at 7:27 PM
Big Pharma: Investment BedrockBig Pharma: Investment Bedrock
finance.yahoo.com - April 12 at 7:27 PM
Pfizer’s 15-month fall: Will the stock ever recover?Pfizer’s 15-month fall: Will the stock ever recover?
kalkinemedia.com - April 12 at 2:26 PM
Pfizer (NYSE:PFE) Stock Price Down 0.8%Pfizer (NYSE:PFE) Stock Price Down 0.8%
marketbeat.com - April 12 at 2:02 PM
7 Old-School Blue-Chip Dividend Stocks Offer Total Return Magic7 Old-School Blue-Chip Dividend Stocks Offer Total Return Magic
247wallst.com - April 12 at 9:53 AM
Pfizers 15-month fall: Will the stock ever recover?Pfizer's 15-month fall: Will the stock ever recover?
invezz.com - April 12 at 9:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novartis logo

Novartis

NYSE:NVS
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.